Nanomedicine · 2012 · 25 citations · 28 references
PharmacyOncologyPharmacologyCancer PharmacologyDrug DeliveryTargeted Drug DeliveryCancer Drug DeliveryCancer ImmunotherapyDrug EncapsulationPharmacokinetics Of Anticancer DrugsTargeted Cancer TherapyTumor BiologyAnticancer ActivityAnticancer Drug LoadingCancer NanotherapyLipid VesiclesTumor Suppression MechanismsTumor Targeting SpecificityTumor-targeted Drug DeliveryTumor-targeted Encapsulation
AIM: The therapeutic potential of epigallocatechin-3-gallate (EGCG), a green tea polyphenol with anticancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study was to determine whether a tumor-targeted vesicular formulation of EGCG would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo. MATERIALS & METHODS: Transferrin-bearing vesicles encapsulating EGCG were administered intravenously to mice bearing subcutaneous A431 and B16-F10 tumors. RESULTS: The intravenous administration of EGCG encapsulated in transferrin-bearing vesicles resulted in tumor suppression in 40% of A431 and B16-F10 tumors. Animal survival was improved by more than 20 days compared with controls. CONCLUSION: Encapsulation of EGCG in transferrin-bearing vesicles is a promising therapeutic strategy.
28
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
Marc Dellian, Dai Fukumura, Michael Leunig et al. · PubMed · 1995 · 1.7K citations
Medicine, Cancer Biology, Oncology +17